GlassScriptPhysician profile
Andrea E Castillo
NPI 1104476647
$4,774.33
in general payments reported to CMS, 2019-2025
37 companies · $2,809 in 2025
The $2,809 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $231 · 2023: $17.79 · 2024: $736 · 2025: $2,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.90 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $693.85 | 2024-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $527.34 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $437.46 | 2021-2025 | |
| Lilly USA, LLC | $349.29 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $336.37 | 2022-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $320.67 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Biohaven Pharmaceuticals, INC. | $277.89 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.99 | 2021-2022 | |
| Edwards Lifesciences Corporation | $203.39 | 2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $139.24 | 2024-2025 | |
| Pfizer INC. | $131.61 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2024 | Quviviq |
| Ucb, INC. | $124.99 | 2025 | Nayzilam |
| Viiv Healthcare Company | $119.85 | 2025 | Apretude |
| Otsuka America Pharmaceutical, INC. | $109.97 | 2024-2025 | Rexulti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $87.03 | 2021 | |
| Daiichi Sankyo INC. | $57.70 | 2024-2025 | Injectafer |
| Boston Scientific Corporation | $54.10 | 2021 | |
| Ani Pharmaceuticals, INC. | $51.93 | 2024 | Purified Cortrophin Gel |
| Forte Bio-Pharma LLC | $50.39 | 2021-2024 | Prolate, Nalocet |
| Biohaven Pharmaceutical Holding Company LTD. | $38.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.29 | 2025 | Takhzyro |
| Nalu Medical, INC. | $24.56 | 2025 | Nalu Neurostimulation System |
| Astellas Pharma US INC | $22.84 | 2025 | Veozah |
| Ultragenyx Pharmaceutical INC. | $22.47 | 2021 | |
| Corcept Therapeutics | $21.96 | 2025 | Korlym |
| Inogen, INC. | $21.87 | 2022 | |
| Lundbeck LLC | $21.45 | 2024 | Rexulti |
| Viatris Specialty LLC | $20.17 | 2025 | Yupelri |
| Almatica Pharma LLC | $18.66 | 2025 | Teriparatide, Loreev Xr |
| Celgene Corporation | $17.79 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $17.57 | 2024 | Voquezna |
| Biotronik Nro, INC. | $17.19 | 2024 | Prospera |
| Gilead Sciences, INC. | $16.46 | 2025 | |
| Inspire Medical Systems, INC. | $15.75 | 2025 | Inspire |
| Phadia US INC. | $15.12 | 2025 | Immunocap |
| Biodelivery Sciences International, INC. | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.